Group 1 - Fiverr International (FVRR) shares have increased by 1% over the past four weeks, closing at $22.33, with a mean price target of $31.9 indicating a potential upside of 42.9% [1] - The mean estimate consists of 10 short-term price targets with a standard deviation of $4.98, where the lowest estimate is $25.00 (12% increase) and the highest is $44.00 (97% increase) [2] - Analysts show strong agreement on FVRR's ability to report better earnings, with a positive trend in earnings estimate revisions, which is a strong predictor of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for FVRR has increased by 20% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - FVRR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement, which is useful for further research [14]

Core Viewpoint - Eupraxia Pharmaceuticals Inc. (EPRX) shows potential for significant upside, with a mean price target of $11.1 indicating a 75.1% increase from its current price of $6.34 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $2.47, suggesting variability in analyst predictions. The lowest estimate is $6.58 (3.8% increase), while the highest is $14.00 (120.8% increase) [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about EPRX's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, two EPS estimates have increased while one has decreased, leading to a 16.1% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - EPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While the consensus price target may not be a reliable measure of potential gains, it does provide a useful guide for price movement direction [14]

Core Viewpoint - The Pennant Group, Inc. (PNTG) shows potential for significant upside, with a mean price target of $33 indicating a 30.7% increase from the current price of $25.25 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $4.82, suggesting variability among analysts [2] - The lowest estimate is $28.00, indicating a 10.9% increase, while the highest estimate is $40.00, suggesting a 58.4% increase [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about PNTG's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.6%, with two estimates moving higher and no negative revisions [12] - PNTG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common tool for investors, they can often mislead and should not be the sole basis for investment decisions [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Ategrity Specialty Insurance Company Holdings (ASIC) closed the last trading session at $18.29, gaining 0.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.8 indicates a 41.1% upside potential.The average comprises five short-term price targets ranging from a low of $23.00 to a high of $30.00, with a standard deviation of $2.95. While the lowest estimate indicates an increase ...

Core Viewpoint - Catalyst Pharmaceutical (CPRX) has shown a 7.2% increase in stock price over the past four weeks, with a mean price target of $34.5 indicating a potential upside of 51.5% from the current price of $22.78 [1] Price Targets and Analyst Consensus - The average price target consists of eight estimates ranging from a low of $32.00 to a high of $40.00, with a standard deviation of $2.67, suggesting a relatively tight clustering of estimates [2] - The lowest estimate indicates a 40.5% increase, while the highest suggests a 75.6% upside, highlighting the variability in analyst predictions [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding CPRX's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates strongly with near-term stock price movements [11] - Over the last 30 days, three earnings estimates have been revised upward, resulting in a 7.3% increase in the Zacks Consensus Estimate [12] Zacks Rank and Investment Potential - CPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13] - While the consensus price target may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - Klaviyo, Inc. (KVYO) shares have increased by 20.7% in the past four weeks, closing at $29.49, with a potential upside of 47.5% based on Wall Street analysts' mean price target of $43.5 [1] Price Targets - The average of 20 short-term price targets ranges from a low of $30.00 to a high of $60.00, with a standard deviation of $5.88, indicating variability among analysts [2] - The lowest estimate suggests a 1.7% increase from the current price, while the highest estimate indicates a 103.5% upside [2] Analyst Sentiment - Analysts show strong agreement on KVYO's ability to report better earnings than previously predicted, which supports the potential for stock upside [4] - A positive trend in earnings estimate revisions has been correlated with stock price movements, suggesting that upward revisions can indicate potential gains [11] Earnings Estimates - Over the last 30 days, seven earnings estimates for KVYO have been revised upward, with no negative revisions, leading to a Zacks Consensus Estimate increase of 191.7% [12] - KVYO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Aris Mining Corporation (ARMN) shows potential for significant upside, with a mean price target of $16.29 indicating a 51.3% increase from the current price of $10.77 [1] Price Targets and Analyst Consensus - The average price target for ARMN ranges from a low of $13.68 to a high of $17.64, with a standard deviation of $1.8, suggesting a relatively tight clustering of estimates [2] - The lowest estimate indicates a 27% increase, while the highest suggests a 63.8% upside [2] - Analysts' price targets should be approached with caution, as they may not always accurately reflect future stock movements [3][10] Earnings Estimates and Analyst Agreement - There is strong agreement among analysts regarding ARMN's ability to report better earnings, which supports the potential for stock price appreciation [4] - Over the past 30 days, the Zacks Consensus Estimate for ARMN's current year earnings has increased by 16.1%, with no negative revisions [12] - ARMN holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Implications of Price Movement - While the consensus price target may not be a reliable indicator of the magnitude of ARMN's potential gains, it does provide a directional guide for price movement [14]

Group 1 - Shares of OppFi Inc. (OPFI) have increased by 3.2% over the past four weeks, closing at $9.94, with a mean price target of $14.5 indicating a potential upside of 45.9% [1] - The mean estimate includes three short-term price targets with a standard deviation of $1.32, where the lowest estimate of $13.50 suggests a 35.8% increase, and the highest estimate of $16.00 indicates a 61% surge [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11][12] Group 2 - The Zacks Consensus Estimate for the current year has risen by 10.6% over the past month, with two estimates increasing and no negative revisions [12] - OPFI holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement [14]

Core Viewpoint - Alto Neuroscience, Inc. (ANRO) has shown a significant price increase of 104.8% over the past four weeks, with a mean price target of $18.71 indicating a potential upside of 62% from the current trading price of $11.55 [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $13.95, where the lowest estimate is $10.00 (indicating a 13.4% decline) and the highest estimate is $50.00 (indicating a potential surge of 332.9%) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding ANRO's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates strongly with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has increased by 5% over the past month, with three estimates revised higher and no negative revisions [12] Zacks Rank and Investment Potential - ANRO currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which indicates a strong potential for upside in the near term [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - Keros Therapeutics, Inc. (KROS) shows potential for significant upside, with a mean price target of $23.13 indicating a 42.8% increase from the current trading price of $16.2 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $5.87, indicating variability among analysts; the lowest estimate suggests a 1.2% decline, while the highest predicts a 116.1% increase to $35.00 [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about KROS's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 366.9% over the past month, with four estimates increasing and no negative revisions [12] - KROS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Caution on Price Targets - While price targets are commonly referenced by investors, they can often mislead; empirical research shows that they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]